• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用易于获得的临床信息,开发改良的列线图以预测初始前列腺活检的结果。

Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.

机构信息

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

出版信息

Urology. 2011 Aug;78(2):392-8. doi: 10.1016/j.urology.2011.04.042. Epub 2011 Jun 25.

DOI:10.1016/j.urology.2011.04.042
PMID:21705045
Abstract

OBJECTIVES

To construct a nomogram that can be used to estimate the risk of prostate cancer (PCa) and high-grade PCa using readily available clinical information for men undergoing initial extended prostate biopsy (PBx). Many nomograms have been developed to predict the outcome of initial PBx. However, most require information not available at the decision to biopsy.

METHODS

From March 2000 to April 2010, 1551 men with a prostate-specific antigen (PSA) of ≤10 ng/mL who underwent initial extended PBx were included in the present study. The nomogram predictor variables were patient age, race, prostate-specific antigen (PSA) level, percent free PSA, family history of PCa, and the digital rectal examination findings. The area under the receiver operating characteristic curve was calculated as a measure of discrimination. The calibration was assessed graphically.

RESULTS

Of the 1551 men, 606 (39.1%) had PCa on biopsy. The mean value for age, PSA, and percent free PSA was 63.4 years, 5.1 ng/mL, and 21.4%, respectively. Also, 25.1% and 7.8% of patients with positive PBx findings had digital rectal examination abnormalities and a positive family history, respectively. The univariate and multivariate analyses suggested that all 6 risk factors were predictors of PCa in the study cohort (P < .05). The area under the curve for all factors in a model predicting PCa was 0.73 (95% confidence interval 0.71-0.76). The area under the curve for predicting high-grade PCa was 0.71 (95% confidence interval 0.69-0.74).

CONCLUSIONS

The present predictive model allows an assessment of the risk of PCa and high-grade PCa for men undergoing initial extended PBx using readily available, noninvasively obtained clinical data.

摘要

目的

构建一个列线图,用于估计接受初次扩展前列腺活检(PBx)的男性前列腺癌(PCa)和高级别 PCa 的风险。已经开发了许多列线图来预测初次 PBx 的结果。然而,大多数需要在活检决策时无法获得的信息。

方法

本研究纳入了 2000 年 3 月至 2010 年 4 月期间,1551 名 PSA 水平≤10ng/ml 的男性,他们接受了初次扩展 PBx。列线图预测变量包括患者年龄、种族、前列腺特异性抗原(PSA)水平、游离 PSA 百分比、PCa 家族史和直肠指检结果。通过计算接收者操作特征曲线下的面积来衡量判别力。通过图形评估校准。

结果

在 1551 名男性中,606 名(39.1%)在活检中发现了 PCa。年龄、PSA 和游离 PSA 的平均值分别为 63.4 岁、5.1ng/ml 和 21.4%。此外,阳性 PBx 结果的患者中有 25.1%和 7.8%分别存在直肠指检异常和阳性家族史。单变量和多变量分析表明,研究队列中的所有 6 个危险因素都是 PCa 的预测因素(P<.05)。预测 PCa 的所有因素模型的曲线下面积为 0.73(95%置信区间 0.71-0.76)。预测高级别 PCa 的曲线下面积为 0.71(95%置信区间 0.69-0.74)。

结论

本预测模型允许使用易于获得的非侵入性临床数据评估接受初次扩展 PBx 的男性 PCa 和高级别 PCa 的风险。

相似文献

1
Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.利用易于获得的临床信息,开发改良的列线图以预测初始前列腺活检的结果。
Urology. 2011 Aug;78(2):392-8. doi: 10.1016/j.urology.2011.04.042. Epub 2011 Jun 25.
2
Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy.孤立性高级别前列腺上皮内瘤变的诊断:预测饱和重活检时检出癌症的列线图的提出。
BJU Int. 2012 May;109(9):1329-34. doi: 10.1111/j.1464-410X.2011.10532.x. Epub 2011 Sep 2.
3
Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients.用于预测日本患者初次前列腺活检阳性概率的列线图的开发。
Urology. 2006 Jan;67(1):131-6. doi: 10.1016/j.urology.2005.07.040.
4
Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.用于预测血清PSA水平低于10 ng/mL的日本患者初次前列腺活检阳性概率的新列线图的开发。
Int J Urol. 2008 Jul;15(7):598-603. doi: 10.1111/j.1442-2042.2008.02058.x. Epub 2008 May 2.
5
Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.利用临床、实验室及超声参数对前列腺特异性抗原水平≤10 ng/mL的患者进行前列腺癌存在情况的预测建模。
Cancer. 2003 Oct 1;98(7):1417-22. doi: 10.1002/cncr.11668.
6
Assessing individual risk for prostate cancer.评估前列腺癌的个体风险。
J Clin Oncol. 2007 Aug 20;25(24):3582-8. doi: 10.1200/JCO.2007.10.6450.
7
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.前列腺特异性抗原(PSA)同工型 p2PSA 显著提高了总 PSA 为 2.0-10ng/ml 的患者初始扩展前列腺活检中前列腺癌的预测能力:一项临床环境中前瞻性研究的结果。
Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5.
8
History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.恶性肿瘤病史是前列腺癌检测的一个预测指标:纳入活检前列线图。
Int J Urol. 2008 Dec;15(12):1055-60. doi: 10.1111/j.1442-2042.2008.02183.x. Epub 2008 Nov 13.
9
A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.一种预测低体积/低级别前列腺癌的列线图:一种用于选择患者进行主动监测的工具。
Cancer. 2007 Dec 1;110(11):2441-7. doi: 10.1002/cncr.23055.
10
Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.用于预测前列腺癌重复活检阳性的列线图的验证
J Urol. 2005 Feb;173(2):421-4. doi: 10.1097/01.ju.0000150522.82760.00.

引用本文的文献

1
Analysis of the Performance and Accuracy of a PSA and PSA Ratio-Based Nomogram to Predict the Probability of Prostate Cancer in a Cohort of Patients with PIRADS 3 Findings at Multiparametric Magnetic Resonance Imaging.基于前列腺特异性抗原(PSA)和PSA比值的列线图在多参数磁共振成像中对前列腺影像报告和数据系统(PIRADS)3类结果患者队列中预测前列腺癌概率的性能和准确性分析
Cancers (Basel). 2024 Sep 5;16(17):3084. doi: 10.3390/cancers16173084.
2
Risk calculators for the detection of prostate cancer: a systematic review.用于检测前列腺癌的风险计算器:一项系统综述。
Prostate Cancer Prostatic Dis. 2024 Sep;27(3):544-557. doi: 10.1038/s41391-024-00852-w. Epub 2024 Jun 3.
3
Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone.
基于 Ga-PSMA PET/CT 的多变量模型,可实现 PSA 灰区中具有临床意义的前列腺癌的高度准确和无创诊断。
Cancer Imaging. 2023 Sep 4;23(1):81. doi: 10.1186/s40644-023-00562-x.
4
Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies.基于超声的放射组学评分用于前列腺癌的活检前预测,以减少不必要的活检。
Prostate. 2023 Jan;83(1):109-118. doi: 10.1002/pros.24442. Epub 2022 Oct 7.
5
Integration of magnetic resonance imaging into prostate cancer nomograms.将磁共振成像纳入前列腺癌列线图
Ther Adv Urol. 2022 May 13;14:17562872221096386. doi: 10.1177/17562872221096386. eCollection 2022 Jan-Dec.
6
Development and validation of a nomogram for predicting prostate cancer in men with prostate-specific antigen grey zone based on retrospective analysis of clinical and multi-parameter magnetic resonance imaging/transrectal ultrasound fusion-derived data.基于临床及多参数磁共振成像/经直肠超声融合衍生数据的回顾性分析,构建并验证用于预测前列腺特异性抗原处于灰色区间男性前列腺癌的列线图。
Transl Androl Urol. 2020 Oct;9(5):2179-2191. doi: 10.21037/tau-20-1154.
7
Prediction of prostate cancer by deep learning with multilayer artificial neural network.基于多层人工神经网络的深度学习对前列腺癌的预测
Can Urol Assoc J. 2019 May;13(5):E145-E150. doi: 10.5489/cuaj.5526. Epub 2018 Oct 15.
8
Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4-10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score.接受经直肠超声引导下前列腺穿刺活检的 PSA 为 4-10 ng/mL 的中国男性前列腺癌的患病率及危险因素:PAMD 评分的应用
Biomed Res Int. 2015;2015:596797. doi: 10.1155/2015/596797. Epub 2015 Oct 18.
9
Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.优化前列腺癌抗原3(PCA3)在初次前列腺活检中诊断前列腺癌的临床应用价值。
BMC Cancer. 2015 Sep 11;15:633. doi: 10.1186/s12885-015-1623-0.
10
The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?生物标志物在前列腺穿刺活检前前列腺癌风险评估中的作用:哪些标志物重要以及应如何使用它们?
World J Urol. 2014 Aug;32(4):871-80. doi: 10.1007/s00345-014-1317-2. Epub 2014 May 14.